Anti-TNF-α inhibitors are now being used in the treatment of pemphigus. An anti-TNF-α chimeric monoclonal antibody, infliximab and a fusion protein of the TNF-α receptor and IgG, etanercept, were successfully used to treat pemphigus.[94,95] Several cholinergic agonists, a Dsg3 peptide and a p38 mitogen-activated protein kinase inhibitor have also been used.
So far, the etiologic factor for the initial production of autoantibodies in pemphigus remains unclear. After elucidation of these events, targeted therapies can be developed for the treatment of pemphigus.
Immunotherapy. 2012;4(7):735-745. © 2012 Future Medicine Ltd.